Superworth

AbCellera Biologics profit margin ABCL

Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.

Net margin, 12 months
n/m
not a meaningful number
Peer median
17.2%

AbCellera Biologics' net margin works out at −249% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024n/an/a
FY2023n/an/a
FY202232.7%44.6%
FY202140.9%54.5%
FY202051.0%66.9%

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a year
Q2 FY26n/an/a
Q1 FY26n/an/a
Q4 FY25n/an/a
Q3 FY25n/an/a
Q2 FY25n/an/a
Q1 FY25n/an/a
Q4 FY24n/an/a
Q3 FY24n/an/a
Q2 FY24n/an/a
Q1 FY24n/an/a
Q4 FY23n/an/a
Q3 FY23n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest AbCellera Biologics' size, closest first, today.

CompanyProfit margin
ABCLAbCellera Biologicsn/m
OGNOrganon3.4%
LQDALiquidia30.7%
ARQTArcutis Biotherapeutics6.1%
INDVIndivior Pharmaceuticals26.7%
NRIXNurix Therapeutics42.0%
PBHPrestige Consumer Healthcare15.6%
KNSAKiniksa Pharmaceuticals International9.6%
LGNDLigand Pharmaceuticals67.9%
HRMYHarmony Biosciences18.9%
AMRXAmneal Pharmaceuticals5.0%
Peer median17.2%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on AbCellera Biologics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.